Moderna begins work on China mRNA manufacturing site

U.S. vaccine maker Moderna (MRNA.O) began construction of its first facility in China this month to manufacture mRNA medicines, the company said on Tuesday.

Moderna's COVID-19 vaccine has yet to be approved in China, but the company said in July it had signed a deal with the city government of China's financial hub Shanghai to work towards opportunities for it to research, develop and manufacture mRNA medicines in the country.